Background Chronic ingestion of ethanol increases acetaldehyde and leads to the production of acetaldehyde-derived advanced glycation end-products (AA-AGE). We evaluated the toxicity of AA-AGE on hepatocytes and studied the role of AA-AGE in the pathogenesis of alcoholic liver disease (ALD). Methods Rat hepatocyte cultures were treated with N-ethyllysine (NEL) or AA-AGE and the cell viability was evaluated using MTT assay. Male Wistar rats were fed with liquid diet containing 5% ethanol for 8 weeks following normal diet for another 12 weeks. A group of animals was sacrificed at 4th, 6th, and 8th week and the remaining animals at 12th, 14th, 16th, 18th, and 20th week. The liver sections were stained for AA-AGE and 4-hydroxy-2-nonenal (4-HNE). Liver biopsy obtained from ALD patients was also stained for AA-AGE and 4-HNE. Results Hepatocyte viability was significantly reduced in cultures treated with AA-AGE compared to NEL treated or control cultures. Severe fatty degeneration was observed during chronic administration of ethanol increasing from 4–8 weeks. The staining of AA-AGE and 4-HNE was correlated with the degree of ALD in both rat and human. In rats, hepatic fatty degeneration was completely disappeared and the staining for both AA-AGE and 4-HNE returned to normal at 12th week of abstinence. Staining for AA-AGE and 4-HNE was completely absent in normal human liver. Conclusions The data demonstrated that AA-AGE is toxic to hepatocytes, but not NEL. Chronic ethanol ingestion produces AA-AGE and reactive oxygen species that contribute to the pathogenesis of ALD. Abstinence of alcohol results in complete disappearance of both AA-AGE and 4-HNE along with fatty degeneration suggesting that AA-AGE plays a significant role in the pathogenesis of ALD.
References
[1]
Beier JI, McClain CJ (2010) Mechanisms and cell signaling in alcoholic liver disease. Biol Chem 391: 1249–1264.
[2]
Gao B, Bataller R (2011) Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 141: 1572–1585.
[3]
Setshedi M, Wands JR, Monte SM (2010) Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev 3: 178–185.
[4]
Yu HS, Oyama T, Isse T, Kitagawa K, Pham TT, et al.. (2010) Formation of acetaldehyde-derived DNA adducts due to alcohol exposure. Chem Biol Interact 188, 367？375.
[5]
Freeman TL, Tuma DJ, Thiele GM, Klassen LW, Worrall S (2005) Recent advances in alcohol-induced adduct formation. Alcohol Clin Exp Res 29: 1310–1316.
[6]
Eriksson CJ (2001) The role of acetaldehyde in the actions of alcohol (Update 2000). Alcohol Clin Exp Res 25: 15S–32S.
[7]
Jeong KS, Soh Y, Jeng J, Felder MR, Hardwick JP, et al. (2000) Cytochrome P450 2E1 (CYP2E1)-dependent production of a 37-kDa acetaldehyde-protein adduct in the rat liver. Arch Biochem Biophys 384: 81–87.
[8]
Brownlee M (1995) Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46: 223–234.
[9]
Vlassara H, Bucala R, Striker L (1994) Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70: 138–151.
[10]
Singh R, Barden A, Mori T, Beilin L (2001) Advanced glycation end-products: a review. Diabetologia 44: 129–146.
[11]
Vlassara H (1997) Recent progress in advanced glycation end products and diabetic complications. Diabetes 46: S19–25.
[12]
Hyogo H, Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, et al. (2007) Elevated levels of serum advanced glycation endproducts in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 22: 1112–1119.
[13]
Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, et al. (1998) Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol 153: 1149–1155.
[14]
Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, et al. (2010) Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroneterol 45: 750–757.
[15]
Takeuchi M, Makita Z, Yanagisawa K, Kameda Y, Koike T (1999) Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol Med 5: 393–405.
[16]
Li J, Liu D, Sun L, Lu Y, Zhang Z (2012) Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J Neurol Sci 317: 1–5.
[17]
Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, et al. (2000) Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 6: 114–125.
[18]
Takeuchi M, Yanase Y, Matsuura N, Yamagishi S, Kameda Y, et al. (2001) Immunological detection of a novel advanced glycation end-product. Mol Med 7: 783–791.
[19]
Takeuchi M, Makita Z (2001) Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo. Curr Mol Med 1: 305–315.
[20]
Takeuchi M, Watai T, Sasaki N, Choei H, Iwaki M, et al. (2003) Neurotoxicity of acetaldehyde-derived advanced glycation end products for cultured cortical neurons. J Neuropathol Exp Neurol 62: 486–496.
[21]
Papeleu P, Vanhaecke T, Henkens T, Elaut G, Vinken M, et al. (2006) Isolation of rat hepatocytes. Methods Mol Biol 320: 229–237.
[22]
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63.
[23]
Schiller CD, Kainz A, Mynett K, Gescher A (1992) Assessment of viability of hepatocytes in suspension using the MTT assay. Toxicol In Vitro 6: 575–578.
[24]
Lieber CS, DeCarli LM (1970) Quantitative relationship between amount of dietary fat and severity of alcoholic fatty liver. Am J Clin Nutr 23: 474–478.
[25]
George J, Tsutsumi M (2007) siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats. Gene Ther 14: 790–803.
[26]
Takeuchi M, Takino J, Yamagishi S (2010) Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy. Curr Drug Targets 11: 1468–1482.
[27]
Popper H, Lieber CS (1980) Histogenesis of alcoholic fibrosis and cirrhosis in the baboon. Am J Pathol 98: 695–716.
[28]
Watabiki T, Tokiyasu T, Yoshida M, Okii Y, Yoshimura S, et al. (1999) Intralobular distribution of class I alcohol dehydrogenase and aldehyde dehydrogenase 2 activities in the hamster liver. Alcohol Clin Exp Res 23: 52S–55S.
[29]
Yamauchi M, Potter J, Mezey E (1988) Lobular distribution of alcohol dehydrogenase in the rat liver. Hepatology 8: 243–247.
[30]
Lieber CS (2004) The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab Rev 36: 511–529.
[31]
Tsutsumi M, Lasker JM, Shimizu M, Rosman AS, Lieber CS (1989) The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver. Hepatology 10: 437–446.
[32]
Lu Y, Cederbaum AI (2008) CYP2E1 and oxidative liver injury by alcohol. Free Radic Biol Med 44: 723–738.
[33]
Wu D, Cederbaum AI (2009) Oxidative stress and alcoholic liver disease. Semin Liver Dis 29: 141–154.
[34]
Cederbaum AI, Lu Y, Wu D (2009) Role of oxidative stress in alcohol-induced liver injury. Arch Toxicol 83: 519–548.
[35]
Nordmann R (1994) Alcohol and antioxidant systems. Alcohol Alcohol 29: 513–522.
